![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
Under the terms of the agreement, Plexxikon grants Novellus rights to research, develop, manufacture and exclusively commercialize PLX8394 worldwide.
Lead Product(s): Plixorafenib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Novellus
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 03, 2020